Showing results (31-40 of 255) with videos related to
Sort By:
Pageof 26
Journal of Neurophysiology|August 15, 2003
GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanismEmilio R Garrido Sanabria, Krystyna M Wozniak, Barbara S Slusher, et al.Advances in Pharmacology (San Diego, Calif.)|February 10, 2025
Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive functionRobyn Wiseman, Kristin L Bigos, Amy F T Arnsten, et al.The Journal of Clinical Investigation|January 4, 2022
Clinical development of metabolic inhibitors for oncologyKathryn M Lemberg, Sadakatali S Gori, Takashi Tsukamoto, et al.Journal of Neurovirology|December 10, 2009
GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicityAjit G Thomas, Amos Bodner, Ghanashyam Ghadge, et al.Journal of Alzheimer'S Disease : JAD|March 19, 2019
The NAAG'ing Concerns of Modeling Human Alzheimer's Disease in MiceKristen R Hollinger, Jesse Alt, Rana Rais, et al.ACS Medicinal Chemistry Letters|November 20, 2014
Structure-Metabolism Relationships in the Glucuronidation of d-Amino Acid Oxidase InhibitorsSarah C Zimmermann, Rana Rais, Jesse Alt, et al.Neurochemical Research|November 22, 2019
Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the BrainJames J Vornov, Diane Peters, Mike Nedelcovych, et al.ACS Medicinal Chemistry Letters|August 29, 2025
Prodrugs 2-(Phosphonomethyl)pentanedioic Acid (2-PMPA) as Orally Available Glutamate Carboxypeptidase II InhibitorsNiyada Hin, Chae Bin Lee, Sadakatali Gori, et al.Brain Research|January 31, 2016
Dose-dependent inhibition of GCPII to prevent and treat cognitive impairment in the EAE model of multiple sclerosisKristen R Hollinger, Jesse Alt, Alison M Riehm, et al.Analytical Biochemistry|May 4, 2010
Bioanalysis of N-acetyl-aspartyl-glutamate as a marker of glutamate carboxypeptidase II inhibitionAjit G Thomas, Camilo J Rojas, Jeanette R Hill, et al.Pageof 26